Drug Report History #138654
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v19-EN | Version v2-EN | |
|---|---|---|
| Language | English | English |
| Date Updated (Changed) | Updated to: 2021-08-26 | Was: 2021-05-03 |
| Drug Identification Number | 02236564 | 02236564 |
| Brand name | LOVENOX WITH PRESERVATIVE 300MG/3ML | LOVENOX WITH PRESERVATIVE 300MG/3ML |
| Common or Proper name | Lovenox Vial | Lovenox Vial |
| Company Name | SANOFI-AVENTIS CANADA INC | SANOFI-AVENTIS CANADA INC |
| Ingredients | ENOXAPARIN SODIUM | ENOXAPARIN SODIUM |
| Strength(s) | 100MG | 100MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS | SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS |
| Packaging size | 1 | 1 |
| Additional packaging sizes | ||
| ATC code | B01AB | B01AB |
| ATC description | ANTITHROMBOTIC AGENTS | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date (Changed) | Updated to: 2021-09-06 | Was: 2021-05-30 |
| Actual start date | ||
| Estimated end date (Changed) | Updated to: 2021-09-13 | Was: 2021-06-30 |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments (Changed) | Updated to: Transportation delay and overselling is leading to a limited supply of product. Allocation will be kept in place to mitigate the anticipated shortage. | Was: Transportation delay - The transportation delay is due to the strike at the Montreal Port. In addition, overselling is leading to a limited supply of product. Allocation will be kept in place to mitigate the anticipated shortage. |
| Health Canada comments |